Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · Real-Time Price · USD
1.220
-0.020 (-1.61%)
May 26, 2026, 1:51 PM EDT - Market open
Entera Bio Revenue
In the year 2025, Entera Bio had annual revenue of $42.00K, down -76.80%.
Revenue (ttm)
$42.00K
Revenue Growth
-76.80%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
22
Market Cap
60.05M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 42.00K | -139.00K | -76.80% |
| Dec 31, 2024 | 181.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
| Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
| Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
| Dec 31, 2019 | 236.00K | -264.00K | -52.80% |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immutep | 5.28M |
| BeyondSpring | 1.88M |
| ImageneBio | 800.00K |
| iBio, Inc. | 300.00K |
| Impact BioMedical | 39.00K |
ENTX News
- 12 days ago - Entera Bio Proxy statement: Proxy filing - Filings
- 17 days ago - Entera Bio files to sell 19.57M ordinary shares for holders - TheFly
- 17 days ago - Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs - GlobeNewsWire
- 18 days ago - Entera Bio Registration statement: Registration filing - Filings
- 18 days ago - Entera Bio Quarterly report: Q1 2026 - Filings
- 18 days ago - Entera Bio Earnings release: Q1 2026 - Filings
- 4 weeks ago - Entera Bio price target lowered to $9 from $10 at H.C. Wainwright - TheFly
- 5 weeks ago - BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity - GlobeNewsWire